- Fee assured
- Verified this account
- Lower GI
- Upper GI
Dr Daniel Krell qualified in medicine at Leeds University Medical School, where he also gained a Bachelor’s degree in microbiology and immunology. He completed his junior doctor training at Guys and St. Thomas’ Hospitals and University College Hospital before undertaking his oncology training at The Royal Free and University College Hospitals in London.
Dr Krell’s DPhil research was undertaken at Oxford University, at the Wellcome Trust Centre for Human Genetics, and was funded by Cancer Research UK and HCA. Dr Krell’s research investigated the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer, with the aim of identifying new therapeutic targets in this area. He continues to be involved in clinical research and clinical trials aimed at identifying new cancer therapies, with a focus on gastrointestinal and hepatobiliary malignancies. He also maintains an interest in cancer genetics and genetic testing for hereditary gastrointestinal cancers, with a particular focus on hereditary colorectal cancer.
Dr Krell has published several peer-reviewed papers in journals such as the British Journal of Cancer and Lancet Oncology. His clinical work focuses on the management of patients with gastric, oesophageal, colorectal, pancreatic, liver and biliary tract cancers using chemotherapy, targeted therapy and immunotherapies, and he is the clinical lead for gastro-oesophageal and hepatobiliary cancer at his institution. He also manages patients with cancer of unknown primary and acts as the clinical lead at his hospital for this.
Areas of interest
colorectal cancer, gastric cancer, oesophageal cancer, pancreatic cancer, liver cancer, cholangiocarcinoma, bile duct cancer, cancer of unknown primary, clinical trials, immunotherapy.
Current NHS consultant posts held
Consultant Medical Oncologist
Royal Free London NHS Foundation Trust
Colorectal, gastric, oesophageal, pancreatic and liver cancers. Neuroendocrine cancer. Immunotherapy.
Multi-Centre randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. Journal of Neuro-Oncology. January 2016
HOT mutation screening in human glioblastoma. Future Science OA, FSO22, DOI: 10.4155/FSO.15.20 (2015).
AT-43* Multi-centre, randomised double-blind phase II study comparing Cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. Neuro-oncology 16: V8-22. 2014. Doi:10.1093/neuonc/neu237
microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur J Cancer. 2015 Jul; 51(11):1389-404.
IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol. 2013 Dec; 9(12): 1923-35
The Malignant Truth. Lancet Oncol. 2013 Jan;14(1): 25-6
Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther. 2012 Oct;12(10): 1275-8
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. PLoS One. 2011; 6(5): e19868
A Retrospective Analysis of Primary Tumour Histology and Survival in Breast Cancer Patients Developing Symptomatic Brain Metastases Treated with Whole Brain Radiotherapy (WBRT) at Mount Vernon Cancer Centre (MVCC). Cancer Research: 2009 Dec; Vol 69, Issue 24, Supplement 3
What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer- A review of the data. J Clin Oncol 27:15s, 2009 (suppl; abstr 1072)
Impact of the effective prevention and management of febrile neutropaenia. Br J Cancer. 2009 Sep;101 Suppl 1:S23-6
- DPhil University of Oxford 2014
- MRCP Royal College of Physicians 2005
- MBChB Leeds University 2003
- BSc Leeds University 2001
Reference number 6075167